Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Prostatic Neoplasms 4Urinary Bladder Neoplasms 1Smoking Cessation 1Prostatic Hyperplasia 1Precancerous Conditions 1Non-melanomatous Skin Cancer 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1

Interventions

Cyclophosphamide 254fludarabine phosphate 165Cytarabine 160Methotrexate 128Busulfan 115Filgrastim 111fludarabine 102Peripheral Blood Stem Cell Transplantation 96Rituximab 94Antilymphocyte Serum 83Etoposide 81Cyclosporine 75Tacrolimus 74Mycophenolic Acid 73Whole-Body Irradiation 72Radiotherapy 70Melphalan 66Vincristine 55Dexamethasone 54Granulocyte Colony-Stimulating Factor 50Methylprednisolone 48Azacitidine 44Alemtuzumab 42Imatinib Mesylate 41Clofarabine 41sargramostim 40Idarubicin 36Daunorubicin 36Cord Blood Stem Cell Transplantation 36Mercaptopurine 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia × polyphenon E × Clear all
NCT00262743 2013-05-30

Green Tea Extract in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia

Mayo Clinic

Phase 1/2 Completed
73 enrolled 12 charts
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡